tag

China's HGR regime still delays foreign-sponsored clinical research despite recent streamlining of review process

Being the first U.S. domestic issuer to have a secondary listing in Hong Kong required navigating difficult SEC and SFC requirements

In fast-paced M&A auctions, potential Chinese buyers must ensure that they are not disadvantaged by the new rules or be perceived as such

Most litigation proceedings have returned to normal in China, but travel restrictions mean that foreign parties must take advantage of online solutions

Hear from the China head of legal at Hongkong Land, one of Asia's leading real estate developers

Counterparty and fit to sue assessments are crucial to an effective litigation readiness strategy

China's international arbitration regime is being brought closer to international best practices

China's military-civil fusion was a major target of U.S. sanctions and export controls in 2020. Chinese companies saw their access to U.S. technology severely restricted by the expanded extraterritoriality of export control rules as well as new lists compiled by various government agencies targetting specific Chinese military end-users.

A Biden administration is likely to be more responsive to stakeholder input and technical dialogue with commercial parties